ALL-REMOTE COMPANY/WILMINGTON, Del. / Dec 18, 2025 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, has been named one of The Software Report’s “Top 50 Software Companies of 2025.” The annual awards program recognizes outstanding companies based on product excellence, organizational strength, company culture and growth, and management team caliber, among other attributes. This marks the fourth consecutive year Phreesia has earned a place on the list and the first time the company has ranked among the Top 10.
“We’re proud to be recognized as one of the top 10 software companies this year,” said Chaim Indig, CEO of Phreesia. “In 2025, we introduced Phreesia VoiceAI, bringing conversational automation to help healthcare organizations manage phone calls and provide a better experience for patients. This honor reflects our continued commitment to making care easier every day for patients and providers alike.”
The Software Report’s Top 50 Software Companies list highlights organizations making a major impact on the software industry in 2025, spanning enterprise platforms, vertical solutions and emerging technologies.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
| Last Trade: | US$17.02 |
| Daily Volume: | 0 |
| Market Cap: | US$1.030B |
December 08, 2025 September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load